Asset
AV-101
Vistagen Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04147949 | phase2 | unknown | 2022-08-01 | 2023-12-01 | VistaGen Therapeutics, Inc. | AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia |
| NCT05280054 | phase1 | unknown | 2021-12-23 | 2022-09-01 | VistaGen Therapeutics, Inc. | AV-101 Alone and in Combination With Probenecid in Healthy Subjects |
| NCT03078322 | phase2 | completed | 2018-03-05 | 2019-10-01 | VistaGen Therapeutics, Inc. | AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression |
| NCT01483846 | phase1 | completed | 2011-12-01 | 2012-09-01 | VistaGen Therapeutics, Inc. | Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers |
FDA applications (0)
This company has no applications containing this asset.